Molecular biology and inhibitors of hepatitis A virus by Debing, Yannick et al.
For Peer Review
 
 
 
 
 
 
Molecular Biology and Inhibitors of Hepatitis A Virus 
 
 
Journal: Medicinal Research Reviews 
Manuscript ID: MED-13-010.R1 
Wiley - Manuscript type: Review Article 
Date Submitted by the Author: n/a 
Complete List of Authors: Debing, Yannick; Rega Institute - University of Leuven, Microbiology and 
Immunology 
Neyts, Johan; Rega Institute - University of Leuven, Microbiology and 
Immunology 
Thibaut, Hendrik; Rega Institute - University of Leuven, Microbiology and 
Immunology 
Keywords: hepatitis A virus, virus replication, immune evasion, atopy, antiviral drugs 
  
 
 
John Wiley & Sons
Medicinal Research Reviews
For Peer Review
MOLECULAR BIOLOGY AND INHIBITORS OF HEPATITIS A VIRUS 1 
Yannick Debing, Johan Neyts* and Hendrik Jan Thibaut 2 
Rega Institute for Medical Research, University of Leuven, Leuven, Belgium 3 
 4 
 5 
 6 
Key words: hepatitis A virus, virus replication, immune evasion, atopy, antiviral drugs 7 
 8 
* Corresponding author: 9 
Johan Neyts 10 
Rega Institute for Medical Research 11 
Minderbroedersstraat 10 12 
B-3000 Leuven 13 
Belgium 14 
Email: johan.neyts@rega.kuleuven.be 15 
Fax: +32.(0)16.33.73.40 16 
Phone: +32.(0)16.33.73.5317 
Page 1 of 40
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
ABSTRACT 18 
Hepatitis A virus (HAV) is a faeco-orally transmitted picornavirus and is one of the main causes of acute 19 
hepatitis worldwide. An overview of the molecular biology of HAV is presented with an emphasis on 20 
recent findings. Immune evasion strategies and a possible correlation between HAV and atopy are 21 
discussed as well. Despite the availability of efficient vaccines, antiviral drugs targeting HAV are required 22 
to treat severe cases of fulminant hepatitis, contain outbreaks and halt the potential spread of vaccine-23 
escape variants. Additionally, such drugs could be used to shorten the period of illness and decrease 24 
associated economical costs. Several known inhibitors of HAV with various mechanisms of action will be 25 
discussed. Since none of these molecules is readily useable in the clinic and since the availability of an 26 
anti-HAV drug would be of clinical importance, increased efforts should be targeted towards discovery 27 
and development of such antivirals. 28 
29 
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1. Introduction 30 
Hepatitis A virus (HAV) is a major cause of enterically-transmitted hepatitis worldwide, posing a global 31 
burden estimated in 2005 at 119 million infections of which 31 million resulted in symptomatic illness 32 
and 34 000 in death.
1
 The virus is transmitted faeco-orally, mainly through close contact with infected 33 
individuals or by consumption of contaminated food and drinking water. The extreme environmental 34 
stability of the HAV particle contributes significantly to its transmission.
2,3
 HAV epidemiology correlates 35 
with poor hygiene and living conditions. Consequently, virtually every adult in developing countries is 36 
seropositive due to childhood infection. On the contrary, in regions with improved hygiene standards, 37 
infection is often postponed to later age. In addition, disease severity is generally age-dependent: 38 
infections are usually mild or asymptomatic in young children, whereas at older age, hepatitis A 39 
frequently presents with classic symptoms of acute hepatitis (e.g. jaundice, fatigue, general malaise,…) 40 
and a higher incidence of fulminant hepatitis, which may require liver transplantation.
4
 Fulminant 41 
hepatitis occurs especially in those aged over 50 for which mortality rates up to 5.4% have been 42 
reported.
5
 Additionally, HAV superinfections in chronic liver disease patients (e.g. hepatitis B or C) are 43 
believed to increase morbidity and mortality,
6-8
 although these findings are still subject to debate.
9
 Since 44 
highly efficient vaccines that provide long-lasting immunity have become available, HAV mortality and 45 
morbidity has decreased dramatically.
8,10
 However, occasional outbreaks of hepatitis A, sometimes 46 
resulting in fatal outcomes, still occur in industrialized countries. For instance, in the last decade, 47 
outbreaks have been linked to the consumption of contaminated green onions, semi-dried tomatoes, 48 
seafood, such as raw oysters and sushi, and other foodstuffs.
11-14
  49 
As posited earlier,
15
 research interest in the molecular biology and pathogenesis of HAV has decreased 50 
substantially since the availability of a safe and efficient vaccine. Nonetheless, HAV remains an intriguing 51 
and poorly understood virus and hepatitis A is still a public health problem in many countries. Here, we 52 
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will review key aspects of the biology of HAV with an emphasis on recent findings and the unique 53 
characteristics of the virus. The potential clinical use of antivirals against HAV will be discussed as well. 54 
2. HAV genome organization and replication cycle 55 
HAV is a non-enveloped, single-stranded RNA virus with a positive-sense genome. Despite the fact that 56 
HAV is classified within the family of the Picornaviridae, it exhibits quite some differences compared to 57 
other members of this family and is consequently the sole member of the genus Hepatovirus.
16
 Based on 58 
phylogenetic analysis of full length VP1 sequences, the single HAV serotype is divided into 6 genotypes 59 
(I-VI).
17
 Genotypes I to III are human and can be subdivided into subgenotypes A and B (and potentially 60 
subgenotype IC
18
), whereas genotypes IV to VI are of simian origin.
17
 The HAV genome (as shown in 61 
figure 1) is approximately 7.5kb in length and consists of a 5’ untranslated region (UTR), a single open 62 
reading frame (ORF) and a 3’-UTR with a polyadenosine-tract. Like other picornaviruses, the HAV 63 
genome lacks a cap structure; instead a VPg protein (3B) is attached to the 5’ end. In the 5’-UTR, six 64 
secondary structure domains can be found: domain I contains a hairpin structure, while the second 65 
domain comprises two stem loop structures followed by a polypyrimidine tract (pY1).
19
 The remaining 66 
domains form the type III internal ribosome entry site (IRES) allowing cap-independent translation of the 67 
viral genome. The single ORF comprises the structural genes (VP1 to VP4 (=P1) and 2A) and the non-68 
structural genes (2B-C and 3A-D). The short 3’-UTR contains two stem loops and/or a pseudoknot 69 
structure which are, together with domains I and II and the polypyrimidine tract of the 5’-UTR, crucial 70 
for viral RNA synthesis.
20
  71 
2.1 Receptor binding and cell entry 72 
In 1996, the HAV cellular receptor (HAVcr-1) was identified on African green monkey kidney cells 73 
(AGMK) as an attachment and probably functional receptor.
21
 Consequently, the human homolog 74 
(HuHAVcr-1) was identified and characterized as a human HAV receptor.
22
 HAVcr-1 is also known to be a 75 
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marker for acute ischemic kidney injury (in this context referred to as kidney injury molecule 1 or KIM-76 
1)
23
 and a regulator of T-cell based immunity (in this context referred to as T-cell immunoglobulin and 77 
mucin domain-containing protein 1 or TIM-1).
24
 Nevertheless, since HAVcr-1 is also expressed on other 78 
organs,
22
 it is likely that additional receptors are required for HAV attachment and entry. For instance, it 79 
has been suggested that TIM-3 promotes HAV entry without being a functional receptor.
25
 In addition, 80 
HAV-specific IgA are reported to mediate infection of hepatocytes via the asialoglycoprotein receptor 81 
(ASGPR).
26
 This and the fact that IgA was also identified as a natural ligand for HAVcr-1
27
 may explain 82 
why (and how) IgA-coated HAV can enter the hepatocytes through both HAVcr-1 and ASGPR, thereby 83 
promoting enterohepatic circulation and continuous (endogenous) reinfections of the liver.
28
 This 84 
phenomenon is thought to play an essential role in prolonged and relapsing cases of hepatitis A. Only 85 
the emergence of avid IgG antibodies can break the cycle and eventually clear the infection.
28
 86 
2.2 Uptake and uncoating 87 
Following receptor-mediated binding to the cell surface, the HAV particle is internalized. This has been 88 
suggested to occur through receptor-mediated endocytosis since HAV infection can be inhibited by 89 
blockers of endosomal acidification such as monensin, ammonium chloride and chloroquine.
29-32
 90 
However, the precise mechanism remains unclear to date. Upon binding to its receptor the particle is 91 
destabilized, thus initiating the uncoating process and releasing the single-stranded RNA into the host 92 
cell cytoplasm.
33
 Uncoating has been reported to be a slow and asynchronous process with a reported 93 
duration of 4 to 10 hours, in contrast to under an hour for poliovirus.
34
 It has been proposed that this 94 
asynchronicity may be due to the fact that the HAV inoculum contains a heterogeneous mixture of 95 
mature virions and provirions. These provirions still require a maturation cleavage (of VP0 into VP2 and 96 
VP4, as discussed below) following entry, prior to uncoating, and might therefore uncoat more slowly 97 
than mature virions.
34,35
 During the uncoating process, dense, non-infectious HAV uncoating 98 
intermediates are formed. Intriguingly, these particles do not appear to have an altered sedimentation 99 
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profile, thereby differing from the typical picornaviral A particle.
36
 Finally, both low pH and Ca
2+
 ions are 100 
reported to play an important role in HAV receptor binding, uncoating and during the maturation 101 
cleavage of provirions following virus entry (as described above).
31,32,35,37
 Upon completion of uncoating, 102 
the single-stranded RNA is released into the host cell by an unknown mechanism. 103 
2.3 Translation 104 
The viral RNA, being released into the cytoplasm, is then translated into a single polyprotein. Similar to 105 
other picornaviruses, HAV employs an IRES, located in the 5’ UTR, to direct cap-independent translation 106 
of the viral genome using the host ribosomal machinery. Most picornaviruses affect the host cell protein 107 
synthesis to favor a more efficient translation of the viral mRNA. This process is mediated by a 108 
proteolytic cleavage of eukaryotic initiation factor 4G (eIF4G), thereby inducing a complete shut-down 109 
of capped mRNA translation.
38
 Intriguingly, unlike for other picornaviruses, it is thought that HAV IRES 110 
depends on eIF4G, as part of an intact eIF4F complex.
39
 The fact that HAV has to compete with an intact 111 
host cell machinery may also explain its poor replication in cell culture (see section 5). However, a recent 112 
publication by Redondo et al. suggested that HAV IRES-driven translation can occur without intact eIF4G 113 
and that another factor may be crucial for this translation.
38
 114 
Next, the translated polyprotein is processed co- and posttranslationally in a series of proteolytic 115 
cleavages into several functional precursor and mature proteins. The primary posttranslational cleavage 116 
occurs at the junction between P1-2A and 2B (instead of the junction between P1 and 2A as for other 117 
picornaviruses) (figure 1).
40
 All other processing steps (except the VP1-2A junction, as discussed below) 118 
are mediated by 3C
pro
 and its functional precursor 3ABC
pro
.
41
 This is different from other picornaviruses 119 
which may use L
pro
, 2A, 3C
pro
 and the 3CD
pro
 precursor.
42
 Intriguingly, HAV protein 2A, unlike for other 120 
picornaviruses, has no proteolytic activity nor does it contain a ribosome-skipping sequence,
42
 but 121 
seems to be implicated in morphogenesis (see section 2.6). 122 
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2.4 Regulating the balance between translation and replication  123 
Since translation of viral proteins and RNA replication are competing processes, they must be balanced 124 
properly to allow efficient viral replication.
43
 In order to tip the balance from translation to replication, 125 
the poly(A)-binding protein (PABP), as part of the eIF4F complex, is cleaved by HAV 3C
pro
. The N-terminal 126 
cleavage product of PABP was shown to have an improved RNA-binding capacity compared to uncleaved 127 
PABP and may act as a dominant negative for IRES-mediated translation, thus favoring viral RNA 128 
synthesis.
44
 Additionally, proteolytic cleavage of the poly(rC)-binding protein PCBP2, which interacts 129 
with the pyrimidine-rich tract pY1 in the HAV 5’-UTR, may also be implicated in regulating the balance 130 
between translation and viral RNA synthesis.
19
 Other enzymes that bind to the HAV IRES are 131 
polypyrimidine tract binding protein (PTB), glyceraldehyde 3-phosphate dehydrogenase and La 132 
autoantigen that respectively enhance, suppress and suppress translation.
45-47
 133 
2.5 Replication 134 
As for most RNA viruses, replication of the viral genome takes places in replication complexes that 135 
consist of rearranged cellular membranes containing both viral and host proteins. Studies revealed 136 
important roles for 2BC precursor and 2C proteins in the membrane rearrangements forming the 137 
replication complexes. These complexes are described as a tubular vesicular network and were thought 138 
to be of endoplasmatic reticulum (ER) origin.
48,49
 However, a recent publication described the 139 
mitochondrial localization of the 3ABC precursor protein suggesting that HAV replication complexes may 140 
be derived from the outer mitochondrial membrane.
50
 In line with this hypothesis, exchanging the 141 
mitochondria-targeting 3A transmembrane domain for the ER-targeting poliovirus 3A transmembrane 142 
domain resulted in loss of replication competence.
51
 143 
Within the replication complexes, the viral genome is transcribed into antisense RNA which 144 
subsequently serves as a template for the production of new viral genomes. During this process, the 3D 145 
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protein functions as an RNA-dependent RNA polymerase. The 3B (VPg) protein serves as a starting point 146 
for primer-independent transcription and is covalently linked to the 5’ genome end. A conserved 147 
replication element near the 5’ end of the 3D
pol
-coding sequence likely directs uridylylation of VPg by 148 
3D
pol
, in such way priming VPg for initiation of RNA replication.
52
 During replication, the 3A/3B junction 149 
remains uncleaved and the transmembrane protein 3A serves as an anchor tethering the growing HAV 150 
RNA strand and associated proteins to the membranes of the replication complex,
42,53
 as is the case for 151 
other picornaviruses.
54
 It has also been reported that the 2C protein of HAV binds to the 3’ end of the 152 
antisense RNA. In this way protein 2C may be implicated in anchoring the negative sense RNA template 153 
to the membranes of the replication complex.
55
 154 
2.6 Capsid assembly 155 
Despite the fact that the multi-tiered capsid assembly process is only poorly understood, HAV differs at 156 
various steps from other picornaviruses. Following the initial cleavage at the 2A/2B junction by 3C
pro
 (as 157 
discussed above), the N-terminal part of protein 2A coordinates proper folding of the P1-2A precursor 158 
protein. This precursor protein is then processed by 3C
pro
 and its stable precursor 3ABC
pro
 into VP0 159 
(consisting of VP4 and VP2), pX precursor (consisting of VP1 and 2A) and mature VP3 protein.
42,56
 These 160 
building blocks assemble into pentamers and subsequently associate with viral RNA to form 161 
preprovirions. In a final processing step, VP0 will be cleaved into VP4 and VP2 and precursor pX into VP1 162 
and 2A, yielding mature virus particles with only VP1, VP2 and VP3 proteins. The processing of pX is 163 
mediated by a yet unknown cellular protease.
57
 Although the cleavage can be performed by extracellular 164 
enzymes like factor Xa and trypsin,
58,59
 maturation can also be executed by the lysosomal proteinase 165 
cathepsin L. This may indicate a role for lysosomal proteinases in maturation cleavage and potential 166 
targeting of HAV provirions to the early lysosomes for maturation cleavage.
59
 On the other hand, VP0 167 
processing is thought to be a self-catalytic process that is dependent on the presence of encapsidated 168 
RNA.
60
 The resulting VP4 is rather small compared to other picornaviruses and lacks an N-terminal 169 
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myristoylation signal.
61
 Note that the mature VP4 protein has never been identified in purified virus 170 
stocks and its role in capsid formation remains unclear.
15,60
  171 
2.7 Release 172 
Hepatitis A virus is an enterically transmitted virus that replicates mostly in hepatocytes before it is 173 
excreted via the bile into the faeces. Despite the fact that the exact details of HAV release remain 174 
elusive, the mechanism seems to differ depending on the cell type infected and is thought to involve 175 
either a vesicle-mediated cellular protein transport pathway or specialized hepatocellular transport 176 
proteins involved in bile secretion.
62
 Blank and colleagues demonstrated that following infection of 177 
polarized human intestinal epithelial Caco-2 cells, release of progeny virus was largely restricted to the 178 
apical membrane.
62
 In this way, virus is secreted mainly into the intestinal lumen resulting in an 179 
amplification of the HAV inoculum in the intestines and thus an increased viral shedding and spreading 180 
of the virus. However, it is still unclear by which mechanism HAV reaches the blood stream. A role for 181 
transcytosis by M cells present in Peyer’s patches in the ileum has been suggested, a mechanism that 182 
was found for poliovirus and reovirus as well.
62
 Another study described that infection of polarized 183 
human hepatocytes occurred most efficiently via the basolateral plasma membrane, after which more 184 
than 95% of progeny virus was exported through the basolateral membrane (into the bloodstream), 185 
rather than through the apical membrane (into the bile channels).
63
 This contrasts with the in vivo 186 
observation that bile and faecal titers are considerably higher than serum titers.
15,64
 Reuptake and 187 
transcytosis of progeny virus by the hepatocytes into the bile channels is suggested as the mechanism 188 
for enteric secretion. 189 
2.8 Particle structure 190 
HAV is a nonenveloped icosahedral particle of approximately 27nm in diameter.
65
 The mature capsid is 191 
composed of 12 pentamers each consisting of 5 copies of VP1, VP2 and VP3. Unlike for other 192 
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picornaviruses, VP4 appears not to be present in mature HAV particles (see section 2.6). Attempts to 193 
produce high-resolution images of HAV particles remained unsuccessful so far. A 2006 review
15
 showed 194 
a medium-resolution image obtained by cryo-electron microscopy suggesting the absence of the well-195 
defined canyon surrounding the 5-fold axis, in this way differing from other picornaviruses. However, 196 
these results have not been confirmed or published separately to date. HAV has a limited number of 197 
neutralization antigenic sites. The immunodominant antigenic site is composed of VP1 and VP3 residues 198 
and is conformation-dependent.
66
 A second antigenic site is the glycophorin A binding site by which HAV 199 
can bind to erythrocytes, causing hemagglutination. This process is optimal at acidic pH, but is impaired 200 
at physiological pH. This suggests that HAV has evolved to escape erythrocyte binding and consequent 201 
clearance.
67,68
 Indeed, a mutant of this binding site displayed increased clearance from the blood and 202 
lower overall fitness, suggesting evolutionary constraints and explaining the low level of antigenic 203 
variability of the glycophorin A binding site.
68
 204 
3. Immune evasion mechanisms 205 
Hepatitis A is clinically characterized by a prolonged asymptomatic phase before clinical illness becomes 206 
apparent and a very limited type I interferon response (only in week 1-2 after HAV challenge).
69
 HAV 207 
replication remains largely undetected by the immune system for several weeks after infection and 208 
intrahepatic RNA was shown to persist for over 48 weeks in experimentally infected chimpanzees.
69
 To 209 
this end, HAV employs several strategies to evade the host immune response which are rather different 210 
from those used by other picornaviruses. 211 
3.1 Targeting MAVS and TRIF 212 
One of these evasion tactics is to ablate the innate immunity’s alarming system that induces IFN 213 
expression. HAV was shown to inhibit double stranded RNA-induced IFNβ gene expression
70
 by 214 
interfering with the retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 215 
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5 (MDA-5) signaling pathways (figure 2).
71
 RIG-I recognizes single-stranded 5’-triphosphate RNA, while 216 
MDA-5 detects single- and double-stranded picornaviral RNA covalently linked to VPg.
72
 Both RIG-I and 217 
MDA-5 use an adaptor protein called mitochondrial antiviral signaling protein (MAVS, also known as IPS-218 
1, VISA or Cardif) that is localized on the outer membrane of the mitochondria.
50
 Upon activation by RIG-219 
I or MDA-5, MAVS recruits and activates TANK-binding kinase 1 (TBK1) and inhibitor of NF-κB kinase ε 220 
(IKKε). TBK1 and IKKε are both responsible for the phosphorylation of IFN regulatory factor 3 (IRF-3), 221 
eventually leading to IRF-3 dimerization, nuclear translocation and induction of IFNβ transcription. HAV 222 
proteins 3ABC
pro 50
 and 2B
72
 have been described to interfere with MAVS, thereby disrupting the innate 223 
cellular antiviral defense mechanism. Precursor protein 3ABC is a stable polyprotein processing 224 
intermediate that requires both the 3A and the 3C
pro
 domain for the cleavage and inactivation of MAVS. 225 
The transmembrane domain of protein 3A ascertains mitochondrial localization while the 3C
pro
 catalytic 226 
site performs the actual proteolytic cleavage of MAVS. Mere 3C
pro
, lacking the 3A domain, is incapable to 227 
perform this proteolysis.
50
 In addition, it has been demonstrated that protein 2B suppressed both MAVS 228 
functioning and the kinase activities of TBK1 and IKKε, thus synergistically suppressing RIG-I/MDA-5 229 
signaling, although the exact mechanism still remains to be elucidated.
72
 230 
Toll-like receptor 3 (TLR3) provides an additional recognition mechanism for double-stranded RNA 231 
(dsRNA). Activation also results in IRF-3 phosphorylation and induction of IFNβ transcription, but unlike 232 
RIG-I and MDA-5, the downstream action of TLR3 is mediated through TRIF (Toll/IL-1 receptor domain-233 
containing adaptor inducing IFNβ) which activates the TBK1 and IKKε kinases. A recent study reported 234 
the proteolytic cleavage of TRIF by the 3CD precursor.
73
 In analogy with the specificity of 235 
3ABC
pro
-induced cleavage of MAVS, 3C
pro
 without the 3D domain is not capable of performing this 236 
cleavage. This suggests that the 3D
pol
 sequence is required to modify the substrate specificity without 237 
requiring the catalytic polymerase activity. In addition, proteolytic cleavage of TRIF cannot be performed 238 
by the 3ABC intermediate.
73
 239 
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Cleavage of TRIF and MAVS has been reported for other picornaviruses as well, e.g. coxsackievirus B3 240 
(MAVS and TRIF)
74
 and enterovirus 71 (TRIF)
75
. Unlike for HAV, 3C
pro
 of both viruses appeared to be 241 
sufficient for proteolysis. Interestingly, both MAVS and TRIF are also cleaved by the HCV NS3/4A 242 
protease. Despite the fact that the HAV and HCV proteases differ in cleavage specificity and are 243 
phylogenetically unrelated, they target the same pair of adaptor proteins, which may be considered a 244 
remarkable example of convergent evolution.
73
 245 
3.2 Coding biases 246 
A second immune evasion strategy employed by HAV can be found in its codon bias or non-uniform 247 
usage of codons during translation.
76
 Due to the lack of mechanisms to induce cellular shut-off, HAV has 248 
to compete with host mRNA for translation (as described above). Within this context, HAV has 249 
strategically adopted a codon bias towards rare codons, resulting in a highly deoptimized coding 250 
usage.
77,78
 This phenomenon contributes considerably to the low replication efficiency of HAV in several 251 
ways and seems to serve multiple purposes: first, the deoptimized codon use may reflect a strategy by 252 
which rare tRNAs are preferred over abundant tRNAs thereby avoiding competition with cellular tRNAs 253 
in the absence of an adequate host cell translation shut off.
77
 Second, due to a decreased translation 254 
and replication rate, the virus is capable of keeping the cellular amount of dsRNA to a minimum, thus 255 
escaping the host cell antiviral response.
78
 In addition, CpG-containing codons are particularly 256 
suppressed in the HAV coding sequence.
79,80
 This particular codon deoptimization is proposed to be 257 
associated with the recognition of unmethylated CpG by the innate immunity as a pathogen marker, 258 
contrary to the methylated CpG pairs of the host. Also in this way, HAV can evade the attention of the 259 
immune system. Third, the use of rare codons, usually grouped in clusters, is important for translation 260 
kinetics as such cluster may lead to a transient translation stop, a phenomenon known as ribosome 261 
stalling.
81
 It has been suggested, that this transient stop may be an important prerequisite for proper 262 
folding of HAV structural proteins thereby contributing to the low antigenic variability and extreme 263 
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environmental stability of HAV.
77,78,82
 Consequently, when HAV is adapted to replicate in vitro under 264 
circumstances of chemically-induced cellular shut-off, the resulting strains (with a ‘re-deoptimized’ 265 
coding sequence) display reduced environmental stability.
83
 Given the preference of HAV for reduced 266 
RNA replication and translation levels, it is now comprehensible why HAV would employ such inefficient 267 
type III IRES:
84,85
 a very efficient IRES would not be compatible with escaping innate immunity and with 268 
the many ribosome stalls during translation.
83
 269 
In conclusion, the coding biases found in the HAV genome may result from evolutionary pressures 270 
towards (i) environmental stability (and thus controlled translation kinetics to obtain a resilient viral 271 
particle) and (ii) evading the host immune system.
79
 Additional insights into the mechanisms at action 272 
would prove very valuable with regards to our understanding of virus evolution and virus-host interplay. 273 
3.3 Modulation of regulatory T cell activity 274 
In addition to manipulation of the innate immunity, HAV also modifies the adaptive immunity through 275 
its receptor binding. HAVcr-1 is a phosphatidylserine (PtdSer) receptor and functions as a potent T-cell 276 
co-stimulatory molecule that regulates activation of and tolerance induction (thus suppressing 277 
autoimmune responses) in T cells.
24
 A recent study reported that HAVcr-1 is constitutively expressed on 278 
regulatory T (Treg) cells.
86
 The function of these specialized T cells is to limit the magnitude of the 279 
immune response to diverse pathogens, in such way avoiding a hyperactive immune response and 280 
subsequent collateral (tissue) damage.
87
 Several micro-organisms activate Treg in order to limit 281 
inflammation and tissue injury, as is the case for chronic HBV and HCV infections.
87
 Conversely, binding 282 
of HAV to its receptor inhibits Treg cell functioning.
86
 In this way, the host is overwhelmed by anti-self-283 
responses since Treg cells normally suppress auto-immune reactions, allowing HAV to escape the 284 
attention of the immune system. In addition, HAV inhibits the production of transforming growth factor 285 
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β by Treg cells, thereby blocking T-effector-mediated anti-HAV responses. Complementary, HAV 286 
stimulates IL-22 production which limits immune-mediated liver damage.
86
 287 
Taken together, by inhibiting Treg function, HAV creates an environment that favors viral replication and 288 
establishment of infection. These findings may also provide an explanation why HAV may elicit auto-289 
immune hepatitis and extrahepatic manifestations including autoimmune hemolytic anemia, even 290 
though these complications are rare.
88
 291 
4. A link between hepatitis A and atopy 292 
The hygiene hypothesis states that the uprising of atopic disease, including asthma, allergic rhinitis and 293 
atopic dermatitis in industrialized countries is due to the increased hygiene.
89
 As HAV serostatus can be 294 
regarded as a hygiene marker, its correlation with atopy was studied. It has been reported by several 295 
groups that HAV infection is negatively correlated with hay fever, asthma and other atopic diseases.
89,90
 296 
However, other studies were unable to replicate such effect.
91,92
 In addition, McIntire et al described 297 
that previous HAV infection may protect against atopy in individuals carrying a 6 amino acid-insertion 298 
(designated 157insMTTTVP) in the gene encoding HAVcr-1 (which is present in 46-64% of the 299 
population).
93
 However, more recent studies failed to fully replicate these results.
94,95
 In addition, 300 
157insMTTTVP appears to increase the susceptibility to severe HAV infection.
96
 A double mechanistic 301 
basis was suggested to (partially) explain this observation: (i) HAV binds more efficiently to the 302 
157insMTTTVP-carrying HAVcr-1, resulting in a more effective receptor and (ii) natural killer T cells 303 
expressing this long form of HAVcr-1 were more cytolytic against HAV-infected hepatocytes.
96
 Thus, the 304 
157insMTTTVP may protect from atopy, but predispose to severe HAV infections. 305 
In conclusion, a possible relationship between a previous HAV infection, protection from atopic disease 306 
and HAVcr-1 polymorphisms is still subject of debate, but represents an interesting area of research. If 307 
HAV truly has a protecting effect, several questions should be addressed: does infection need to occur 308 
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during childhood? Has vaccination a similar effect? Can this relationship be used in finding a therapeutic 309 
target for atopy? Insights into this relationship may prove crucial in combating the rise of atopic disease 310 
in industrialized countries. 311 
5. Cell culture 312 
Unlike for most picornaviruses, culturing wild-type (wt) HAV in cell culture has proven to be quite a 313 
challenge as these strains replicate only very marginally in vitro (e.g. reference 97). HAV can be adapted 314 
to growth in cell culture through serial passaging; a process that introduces cell culture-adapting 315 
mutations stepwise into the viral genome. Such mutations have been found in the P2 region (especially 316 
in 2B and 2C)
98,99
 and in the 5’-UTR,
100,101
 but also in other parts of the genome.
98
 Intriguingly, these cell 317 
culture-adapting mutations result in HAV strains that are highly attenuated in vivo (e.g. references 318 
99,100). A major advance in culturing HAV was the selection of a Huh7 cell line (designated Huh7-A-I) 319 
which allows genetically stable growth of wt HAV without the accumulation of cell culture-adapting 320 
mutations.
104
 321 
Although wt HAV does not induce a cytopathic effect (CPE) in cell culture, cytopathic strains may arise 322 
during prolonged serial passaging.
105,106
 CPE appears to be cell type-specific and is mostly found in 323 
monkey kidney cell lines like FRhK-4 and BS-C-1. These selected virus strains induce apoptosis through 324 
ribosomal RNA degradation by RNase L
107,108
 and consequent caspase activation.
109
 Interestingly, it 325 
seems possible to induce CPE with cell culture-adapted non-cytopathic strains under specific conditions 326 
of lower temperature (<34°C) and decreased cell density, both in FRhK-4 and human A549 cells.
110
 327 
Similarly, we observed CPE for the PA21 strain (genotype IIIa) in FRhK-4 cells under these conditions 328 
(unpublished results). 329 
 330 
Page 15 of 40
John Wiley & Sons
Medicinal Research Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
 
6. The need for antivirals? 331 
Despite the availability of an efficient vaccine, an antiviral drug against HAV would be of great use. First, 332 
since HAV growth in vitro is rather limited, the production of vaccines remains a painstaking process 333 
which in part explains the high cost.
15
 This cost is particularly a problem in relatively poor regions with 334 
improved hygiene where infections occur at later age and consequently are more severe.
4
 Second, 335 
antivirals could shorten the period of illness and decrease symptoms and associated economic costs in 336 
infected unvaccinated patients. Early treatment of these infected unvaccinated persons may also 337 
prevent severe cases of fulminant hepatitis. Third, an antiviral could be a useful tool in rapidly 338 
containing epidemics. Lastly, the potential emergence of vaccine-escape variants has been reported 339 
recently;
18
 an anti-HAV drug could therefore be instrumental in halting the spread of such virus strains. 340 
In conclusion, there is certainly a need for antiviral drugs for hepatitis A, given that they are safe, 341 
efficacious and preferably cheap. 342 
Research into HAV antiviral drug discovery was mostly performed during the late eighties and early 343 
nineties. Afterwards, research efforts and funding waned due to the introduction of vaccines,
15
 although 344 
some interesting work has been done on amantadine and 3C
pro
 inhibitors in the last decade. An 345 
overview of the most relevant inhibitors is presented here (also see table 1). 346 
6.1 Interferon 347 
In 1984, IFNβ was already demonstrated to efficiently inhibit the replication of HAV in human embryo 348 
fibroblasts.
111
 HAV-infected cells were completely cleared following 5 passages with 1000 IU/ml of IFNβ. 349 
Later, another study reported an effective concentration 50 (EC50, minimal concentration required to 350 
reduce virus replication by 50%) of 90 IU/mL and a selectivity index (SI = 50% cytotoxic concentration 351 
(CC50)/EC50) of more than 100 for IFNα-2a.
112
 In addition to the in vitro activity, a case study describes 352 
the in vivo efficacy of IFNβ in three patients with fulminant hepatitis A and one patient with severe 353 
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hepatic failure due to HAV. Following a treatment with 3 million units per day, liver functioning 354 
ameliorated and all 4 patients survived.
113
 However, in addition to its high price and parenteral 355 
administration, the clinical use of IFN is associated with severe side effects hampering usage in less 356 
developed regions. 357 
6.2 Amantadine 358 
Amantadine was initially thought to inhibit HAV by increasing the intravesicular pH. However, its 359 
antiviral effect required an extended incubation when compared to NH4Cl and other lipophilic amines 360 
(e.g. methylamine, dansylcadaverine).
29
 In line with these findings, inhibition of HAV IRES-dependent 361 
translation was later reported as a mechanism of action (MOA).
114
 A follow-up study confirmed the 362 
moderate activity of amantadine in cell-based assays.
115
 In addition, an increased effect was observed 363 
when amantadine was combined with IFNα or IL-29 (IFNλ1).
115,116
 However, in addition to a fairly limited 364 
effect in vitro (EC50 of 58µM and a SI around 5
117
), pharmacokinetic studies demonstrated maximum 365 
plasma concentrations (Cmax) following a multiple dosage scheme well below the reported EC50,
118
 366 
limiting its use in a clinical context. 367 
6.3 The curious case of guanidine HCl 368 
For guanidine HCl, a protein 2C-targeting anti-enterovirus inhibitor, mixed results were reported. The 369 
earliest publication detected no inhibition at 1 and 2mM,
119
 but other groups found moderate inhibition 370 
(around 50%) following treatment with 3mM
120
 or 2.5mM.
107
 Cho and colleagues reported reversible 371 
inhibition at 2mM but also reported enhancement of replication at 0.1-1mM.
121
 Conversely to these 372 
results, Yi et al reported strong inhibition of viral replication at concentrations as low as 0.1mM.
99
 373 
Several factors may explain the inconsistency of these data: (i) mutations in the different viral genomes 374 
studied, specifically in the 2C region; (ii) the cell type used in the antiviral assay; (iii) the multiplicity of 375 
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infection (MOI), which was found to be an important determinant for the antiviral activity;
107
 and (iv) 376 
the detection method employed. 377 
6.4 Miscellaneous small molecule inhibitors of the HAV replication cycle 378 
Only limited information is available on other compounds with anti-HAV activity. Early steps of the 379 
replication cycle can be blocked by iota-carrageenan, which probably functions as an inhibitor of virus 380 
attachment and receptor binding.
122
 Atropine, at 1.7mM, proved to moderately reduce HAV replication 381 
by targeting the early steps of the HAV replication cycle as well (attachment and possibly uncoating).
123
 382 
Due to toxicity and limited antiviral activity, the clinical potential of both compounds is low. For 383 
glycyrrhizin, an aqueous extract of the licorice root, an EC50 of 325µM and a SI of 15 were reported.
117,124
 384 
Subsequent studies suggested inhibition of membrane penetration as the putative MOA.
124
 In addition 385 
to its anti-HAV activity, glycyrrhizin proved also to be active against a relatively large panel of other 386 
viruses, including HBV, HCV, HSV and HIV, with several proposed mechanisms of action, as reviewed by 387 
Fiore et al.
125
 However, glycyrrhizin may cause pseudohyperaldosteronism due to its aldosterone-like 388 
effects. In addition, the compound is readily metabolized following oral and intravenous administration 389 
and the attained plasma concentrations are considerably lower than the reported EC50,
126
 hampering 390 
clinical use for treatment of HAV-infected patients. 391 
Probably the most potent small molecules reported thus far are 4’,6-dichloroflavan and 4’,6-392 
dichloroisoflavan (EC50 values of 6nM).
127
 Inhibition of cell entry or viral uncoating were posited as 393 
possible mechanisms of action for the antiviral activity against HAV. These drugs were also found to be 394 
effective against rhinoviruses and poliovirus in vitro.
127
 However, 4’,6-dichloroflavan failed to protect 395 
volunteers from experimental rhinovirus infection when administered both orally or intranasally,
128,129
 396 
raising doubts concerning its in vivo efficacy against HAV as well. 397 
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Other early stage inhibitors include chlorpromazine and chloroquine.
31
 The former is thought to block 398 
endocytosis of non-clathrin-coated vesicles, while the latter inhibits endosome acidification.
31
 399 
Monensin, another endosome acidification blocker, yielded minor to extensive inhibition of HAV 400 
replication in different studies.
30,31,62
 401 
In addition to early stage inhibitors, several other HAV inhibitors were identified to target different steps 402 
of the intracellular replication process including RNA synthesis, translation and capsid assembly. 403 
However, the information on their precise MOA is very limited. For instance, ribavirin was demonstrated 404 
to have a moderate effect at 100µM,
130
 showing an EC50 of 94µM and a selectivity index of around 4.
117
 405 
Improved anti-HAV activity was reported for pyrazofurin, an orotidine 5'-monophosphate decarboxylase 406 
inhibitor, but further development was halted due to toxicity (interference with nucleotide 407 
metabolism).
117
 Protamine reduced HAV replication with 97% at 100µg/mL and was suggested to 408 
function as a RNA polymerase inhibitor.
123
 In addition, inhibitors of oxidative phosphorylation and 2-409 
deoxy-D-glucose, a glycolysis inhibitor, were identified as inhibitors of HAV replication by unknown 410 
mechanisms.
30
 Other inhibitors include brefeldin A
62,107
 and cycloheximide,
107
 inhibitors of ER-to-golgi-411 
transport and protein synthesis respectively. A moderate anti-HAV activity was also reported for 412 
amphotericin B
131
 and methisoprinol,
132
 drugs used against fungal infections and as an 413 
immunomodulator in the treatment of subacute sclerosing panencephalitis respectively. However, no 414 
data are available on the MOA. 415 
In recent years, several new anti-HAV compounds were synthesized, but the antiviral activity remained 416 
rather limited.
133–135
 Other papers reported highly potent inhibitors of HAV replication, but did not 417 
report toxicity data, making it impossible to judge whether or not these are selective inhibitors.
136–138
 418 
6.5 Rational design of 3C
pro
 inhibitors 419 
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Considerable efforts have been undertaken to rationally design and develop inhibitors for HAV and 420 
human enterovirus 3C
pro
 and the related coronavirus 3C-like protease (3CL
pro
).
139
 These enzymes have a 421 
topology comparable to that of the chymotrypsin-like serine proteases, but are in fact cysteine 422 
proteases.
139
 Consequently, the general research strategy is to introduce thiol-reactive groups into the 423 
catalytic site. Several of such protease inhibitors have been developed over the years, both modified 424 
peptides and non-peptidic analogs. Despite the fact that the modified peptides are easier to design (by 425 
merely mimicking the natural protease substrate), non-peptidic and peptidomimetic inactivators are 426 
preferred, since they can be modified in order to increase stability and cellular and gastro-intestinal 427 
uptake, properties that are difficult to attain for peptides. A similar approach has already been applied 428 
to rhino- and enterovirus 3C
pro
 and resulted in the molecule rupintrivir which was halted after 429 
unsuccessful phase II clinical trials.
140
 430 
The first HAV 3C
pro
 inhibitors developed were modified peptides based on the acetyl-Leu-Ala-Ala 431 
sequence, serving as competitors for the natural peptide substrate Leu-Arg-Thr.
141
 Based on these 432 
findings, peptidyl aldehyde and monofluoromethylketone (FMK) inhibitors were developed.
142,143
 433 
Resolving the crystal structure of HAV 3C
pro
 in complex with a peptidyl FMK inhibitor indicated that the 434 
inhibitor covalently binds the catalytic cysteine.
144
 One of these peptidyl FMK inhibitors was also tested 435 
ex vivo and was shown to reduce HAV replication by 96%.
143
 However, cellular uptake appeared to be a 436 
major problem. In addition, several azaglutamine derivatives were found to be irreversible peptidic 437 
inhibitors.
145
 438 
On the other hand, several non-peptidic antagonists were reported as well. Asymetric 439 
azodicarboxamides were found to be irreversible inhibitors of HAV and HRV 3C
pro
.
146
 Serine and 440 
threonine β-lactones also inhibited HAV 3C
pro
.
147,148
 Other inhibitors include monophenyl 441 
pseudoxazolones of glycine (IC50 of 4-6µM)
149
 and cathepsin K inhibitor-based keto-glutamines.
150
 Lastly, 442 
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halopyridinyl esters were reported as the most potent non-peptide HAV 3C
pro
 inhibitors thus far with 443 
IC50’s as low as 53nM.
151
 444 
Although recent publications in this field seem to focus increasingly on HRV 3C
pro
 and coronavirus 445 
3CL
pro
,
152
 it would be wise not to neglect possible anti-HAV activity for potential future (off-label) use of 446 
a marketed HRV or coronavirus protease inhibitor for severe HAV infections. 447 
6.6 RNA interference 448 
RNA interference (RNAi) has been suggested as a future treatment of severe HAV infections.
153
 Small 449 
interfering RNA (siRNA) targeting non-structural genes can effectively block replication.
153,154
 Inhibition 450 
was also reported when targeting domains IIIC and V of the HAV IRES.
155
 Three consecutive applications 451 
of siRNA over 14 days resulted in a 3 log10
 
infectivity titer reduction in persistently infected cells. 452 
However, resistance emerged fairly quickly through mutation of the target site, necessitating 453 
combination of different siRNA’s.
154
 Once clinical RNAi therapy would be an established treatment for 454 
other (infectious) diseases, it would be interesting to further explore this for hepatitis A. However, such 455 
clinical applications of RNAi are currently still at the experimental stage. 456 
6.7 Novel antiviral assays 457 
We recently reported the development of three assays to screen for and identify small molecule 458 
inhibitors of HAV replication.
156
 A CPE reduction assay based on the cell culture-adapted HM175/18f 459 
strain (genotype IB) is amendable to high-throughput screening. RT-qPCR-based virus yield assays for 460 
HM175/18f and genotype IIIA strain PA21 were developed as well, allowing for confirmation and further 461 
characterization of the antiviral activity of selected molecules. The known inhibitors IFNα and 462 
amantadine were used to validate these assays. Using these assays, three enterovirus inhibitors with 463 
different targets were evaluated for anti-HAV activity. Pleconaril, a known capsid binder,
140
 yielded (not 464 
unexpectedly) a very limited activity; inhibition by rupintrivir, a 3C
pro
 inhibitor, proved to be strain-465 
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dependent
156
 and enviroxime, a direct inhibitor of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) that 466 
induces resistance mutations in enterovirus protein 3A,
157
 was inactive in all 3 systems. Recently, 467 
PI4KIIIβ has been identified as an essential host factor in the replication strategy of enteroviruses. 468 
Following recruitment by enterovirus protein 3A to ER-derived organelle membranes, a 469 
phosphatidylinositol-4-phosphate (PI4P)-rich environment is created, promoting viral RNA replication. 470 
The observation that HAV protein 3A is targeted towards the outer mitochondrial membrane instead of 471 
the ER,
50
 together with the observed lack of activity for enviroxime in 2 different cell lines,
156
 suggests 472 
that PI4KIIIβ kinase activity does not play a role in HAV replication. 473 
6.8 Small animal models 474 
A small animal model would be an additional prerequisite for the development and validation of anti-475 
HAV compounds. The host range of HAV is restricted to humans and several non-human primates, e.g. 476 
tamarins and chimpanzees.
158
 Some efforts have been undertaken towards the development of small 477 
animal models, e.g. virus adaptation to mouse cell lines or infection of guinea pigs.
159,160
 However, so far 478 
no robust model for clinical hepatitis A is available. Very recently, it has been found that the chimeric 479 
SCID/Alb-uPA mouse model, which supports the engraftment and proliferation of transplanted human 480 
hepatocytes, is susceptible to HAV infection (Pang D, personal communication). Despite the fact that 481 
these results still need to be published, they could represent a major leap forward for anti-HAV 482 
research. 483 
7. Conclusion 484 
Despite the fact that hepatitis A is a vaccine-preventable disease and infections are usually mild, 485 
continued attention for this pathogen is warranted. Outbreaks and occasional cases of fatal fulminant 486 
hepatitis A still occur and as the age of infection shifts upwards, the severity of the infection increases as 487 
well. Morbidity and mortality may also increase in patients with chronic liver disease, e.g. due to HBV or 488 
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HCV. Additionally, a recent report warned for the potential emergence of vaccine-escape variants.
18
 489 
Taken together, these reasons warrant continuation and expansion of the current vaccination programs, 490 
but also the development of antiviral drugs against HAV, even though this may not be particularly 491 
interesting from a commercial point of view. So far no potent or selective inhibitors have been reported. 492 
We therefore propose to focus antiviral efforts on marketed drugs and antivirals that are currently in 493 
clinical development. Off-label use of such drug would be a much appreciated therapy. In fact, we are 494 
currently employing our CPE reduction assay for screening of a library of FDA approved/marketed drugs 495 
and with promising results so far. Also on the fundamental biology level, HAV remains a largely 496 
understudied virus, despite many interesting features. Further investigation could provide unique 497 
insights into pathogenesis, tissue tropism determinants and replication strategies for HAV and 498 
picornaviruses in general.  499 
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10. Figure legends 904 
Figure 1: HAV genome organization and proteolytic processing of the structural proteins. (IRES = internal 905 
ribosome entry site, UTR = untranslated region) 906 
Figure 2: Inhibition of IFNβ transcription by HAV through proteolytic cleavage of MAVS (by 3ABC) and 907 
TRIF (by 3CD) and through direct inhibition of MAVS, IKKε and TBK1 (by 2B). (dsRNA = double-stranded 908 
RNA, IKK = inhibitor of NF-κB kinase, IRF-3 = interferon regulatory factor 3, MAVS = mitochondrial 909 
antiviral signaling protein, MDA-5 = melanoma differentiation-associated gene 5, RIG-I = retinoic acid-910 
inducible gene I, TBK1 = TANK-binding kinase 1, TLR3 = toll-like receptor 3, TRIF = Toll/IL-1 receptor 911 
domain-containing adaptor inducing IFNβ) 912 
913 
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Figure 1: HAV genome organization and proteolytic processing of the structural proteins. (IRES = internal 
ribosome entry site, UTR = untranslated region)  
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Figure 2: Inhibition of IFNβ transcription by HAV through proteolytic cleavage of MAVS (by 3ABC) and TRIF 
(by 3CD) and through direct inhibition of MAVS, IKKε and TBK1 (by 2B). (dsRNA = double-stranded RNA, 
IKK = inhibitor of NF-κB kinase, IRF-3 = interferon regulatory factor 3, MAVS = mitochondrial antiviral 
signaling protein, MDA-5 = melanoma differentiation-associated gene 5, RIG-I = retinoic acid-inducible gene 
I, TBK1 = TANK-binding kinase 1, TLR3 = toll-like receptor 3, TRIF = Toll/IL-1 receptor domain-containing 
adaptor inducing IFNβ)  
190x142mm (300 x 300 DPI)  
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 Antiviral activity Toxicity SI (putative) target Reference 
IFNα-2a EC50: 90 IU/mL CC50: >10000 IU/mL >100 Induction of antiviral state 112 
Amantadine EC50: 58µM CC50: 310µM 5.3 HAV IRES-mediated 
translation 
117 
Guanidine HCl Variable inhibition between 0.1-3mM ND ND Protein 2C 99, 107, 119-121 
Iota-carrageenan EC50: 2.5µg/mL CC50: >1000µg/mL >400 Attachment 122 
Atropine 84% reduction in viral titer at 1.7mM CC50: >3.5mM ND Attachment and/or 
uncoating 
123 
Glycyrrhizin EC50: 325µM CC50: 5mM 15 Membrane penetration 117 
4,6'-dichloroflavan EC50: 6nM CC50: 45µM 7500 Entry and/or uncoating 127 
4,6'-dichloroisoflavan EC50: 6nM CC50: 90µM 15000 Entry and/or uncoating 127 
Ribavirin EC50: 94µM CC50: 430µM 4.6 Inosine 5’- monophosphate 
dehydrogenase 
117 
Pyrazofurin EC50: 0.62µM CC50: 28µM 45 Orotidine 5'-monophosphate 
decarboxylase 
117 
Protamine 97% reduction in viral titer at 100µg/mL CC50: 200µg/mL ND RNA polymerase 123 
Ac-LAAQ’-fluoromethylketone 96% reduction in viral titer at 5µM ND ND Protein 3C
pro 
143 
Halopyridinyl ester EC50: 53nM ND ND Protein 3C
pro
 151 
Table 1: Overview of reported inhibitors of HAV with (putative) targets and calculated values for 50% effective concentrations (EC50), 50% inhibitory 
concentrations (IC50), 50% cytotoxic concentrations (CC50) and selectivity indices (SI) when provided. ND = not determined 
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